Small spleen peptides (primarily thymosins including Tβ4) convert dendritic cells to a tolerogenic state by modulating extracellular ATP profiles, inhibiting psoriatic arthritis progression even in the presence of TNFα.
Tolerogenic even against TNFαSSPs converted dendritic cells to tolerogenic state and inhibited psoriatic arthritis progression even in the presence of the powerful inflammatory cytokine TNFα
What the researchers found
Small spleen peptides (thymosins/Tβ4) transform dendritic cells into tolerogenic cells by modulating extracellular ATP synthesis and degradation profiles, with the adenosine receptor mediating the tolerogenic phenotype, and in vivo administration inhibits psoriatic skin inflammation.
Why it matters
Current autoimmune treatments often broadly suppress the immune system, increasing infection risk. These spleen-derived peptides offer a more elegant approach — reprogramming specific immune cells toward tolerance rather than blanket suppression. If developed therapeutically, they could treat autoimmune diseases with fewer side effects.
The numbers in context
SSPs maintained tolerogenic DC function even in the presence of pro-inflammatory TNFα. Regulatory T cell induction was confirmed.
How the study worked
SSP composition was analyzed (thymosins identified as primary constituents). Real-time extracellular ATP levels were measured in dendritic cells under tolerogenic vs. immunogenic stimulation. Recombinant thymosin peptides were compared to SSPs for arthritis inhibition. Adenosine receptor involvement was tested pharmacologically. In vivo efficacy assessed in psoriatic skin inflammation model.
Who was studied
Dendritic cell cultures
What this study cannot tell us
The natural SSP extract outperformed recombinant peptides, suggesting unknown synergistic components — making therapeutic development more complex. Mouse models of psoriasis don't perfectly replicate human disease. The specific thymosin peptides and their optimal ratios for therapeutic effect are not yet defined. Long-term effects of tolerance induction not assessed.
How to read the evidence
Preliminary evidence from a combination of in vitro mechanistic studies and in vivo animal models. The concept is compelling but translation to human autoimmune disease therapy requires further development.
When this study was published
Published in 2024, advancing understanding of thymosin-mediated immune tolerance with a novel ATP/adenosine signaling mechanism.
The bigger picture
The balance between extracellular ATP (inflammatory signal) and adenosine (anti-inflammatory signal) is an ancient immune regulatory mechanism. This study shows that thymosin peptides can manipulate this balance to tip dendritic cells toward tolerance — a finding with implications far beyond psoriasis. Autoimmune diseases like rheumatoid arthritis, lupus, and multiple sclerosis all involve loss of immune tolerance, making this mechanism broadly relevant.
Questions still open
- What specific combinations of thymosin peptides in SSPs produce the synergistic tolerogenic effect?
- Could SSPs or their active components be developed as treatments for other autoimmune diseases like rheumatoid arthritis or lupus?
- Does chronic administration maintain immune tolerance without increasing susceptibility to infections or cancer?
Common questions
What are thymosins and why do they come from the spleen?
How is this different from current autoimmune treatments?
Read the original research
Small Spleen Peptides (SSPs) Shape Dendritic Cell Differentiation through Modulation of Extracellular ATP Synthesis Profile.
Biomolecules, 14(4)
Citation
Wixler, Viktor; Leite Dantas, Rafael; Varga, Georg; Boergeling, Yvonne; Ludwig, Stephan. (2024). Small Spleen Peptides (SSPs) Shape Dendritic Cell Differentiation through Modulation of Extracellular ATP Synthesis Profile.. Biomolecules, 14(4). https://doi.org/10.3390/biom14040469